U.S. Stem Cell (USRM) stock price, revenue, and financials

U.S. Stem Cell market cap is $16 m, and annual revenue was $6.70 m in FY 2018

$16 M

USRM Mkt cap, 25-Jan-2021

$156.6 K

U.S. Stem Cell Revenue Q3, 2019
U.S. Stem Cell Gross profit (Q3, 2019)19.2 K
U.S. Stem Cell Gross profit margin (Q3, 2019), %12.3%
U.S. Stem Cell Net income (Q3, 2019)-1.6 M
U.S. Stem Cell EBIT (Q3, 2019)-1.6 M
U.S. Stem Cell Cash, 30-Sept-201978.1 K
U.S. Stem Cell EV17.4 M

U.S. Stem Cell Revenue

U.S. Stem Cell revenue was $6.70 m in FY, 2018

Embed Graph

U.S. Stem Cell Income Statement

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

3.5k3.5k40.5k2.7k4.1k4.2k20.1k322.6k497.0k579.5k489.6k565.3k557.6k710.9k678.2k729.8k1.2m1.4m1.5m1.7m1.8m1.5m1.3m1.3m156.6k

Cost of goods sold

139.0139.0417.094.4k107.1k523.2k247.6k223.6k243.9k154.4k235.4k332.5k344.6k400.6k482.9k503.8k567.2k544.4k522.1k506.0k137.4k

Gross profit

3.4k3.4k40.1k228.1k389.9k56.3k241.9k341.7k313.7k556.6k442.9k397.3k810.4k985.3k1.0m1.2m1.3m959.5k786.7k792.0k19.2k

Gross profit Margin, %

96%96%99%71%78%10%49%60%56%78%65%54%70%71%68%71%69%64%60%61%12%

R&D expense

107.6k92.6k96.7k93.9k106.9k164.0k172.4k158.4k9.9k15.5k8.6k50.1k130.4k12.8k3.5k4.0k1.8k1.1k7.4k3.8k1.3k2.6k599.0420.0531.0

General and administrative expense

556.5k585.7k468.1k325.2k678.0k370.5k439.4k940.4k838.3k831.4k1.5m998.1k690.2k563.7k565.8k696.7k1.4m832.5k782.3k2.0m1.2m2.1m1.2m1.2m825.6k1.6m

Operating expense total

674.4k686.0k569.2k523.0k788.2k535.3k612.3k1.1m849.0k848.0k1.5m1.0m821.9k577.8k570.5k701.9k1.4m852.4k842.9k2.1m1.2m2.1m1.2m1.2m1.3m1.6m

Depreciation and amortization

10.3k7.7k4.3k3.4k769.0481.077.0863.01.1k1.8k1.3k1.3k1.3k1.2k1.2k1.5k18.8k53.3k52.9k524.0

EBIT

(671.0k)(682.7k)(529.1k)(520.3k)(784.1k)(531.1k)(592.1k)(1.1m)(620.9k)(458.0k)(1.5m)(807.6k)(480.2k)(264.1k)(13.9k)(259.0k)(1.0m)(41.9k)142.3k(1.1m)(9.3k)(823.3k)(218.8k)(399.1k)(534.1k)(1.6m)

EBIT margin, %

(19199%)(19533%)(1307%)(19358%)(19257%)(12669%)(2942%)(192%)(92%)(253%)(165%)(85%)(47%)(2%)(38%)(140%)(4%)10%(70%)(1%)(45%)(15%)(30%)(41%)(1020%)

Interest expense

492.5k777.3k429.2k252.5k342.0k352.4k709.4k48.0k1.3m6.6k6.5k240.6k1.4m142.7k349.4k93.9k660.4k2.4m566.9k125.3k129.9k421.2k112.2k274.1k305.0k48.2k

Interest income

475.01.8k11.4k6.1k819.0939.031.7k3.2k10.1k2.5k22.3k69.011.0k

Investment income

4.0k8.3k11.6k15.9k15.3k54.7k59.4k79.6k39.4k95.3k7.8k160.2k100.9k26.3k(33.5k)

Pre tax profit

(1.3m)(1.6m)(946.9k)(760.3k)(1.1m)(518.9k)(750.3k)(1.1m)677.4k(451.4k)(1.5m)(1.0m)886.6k(121.4k)(363.3k)(352.9k)(1.7m)(2.5m)(424.6k)(931.7k)(139.2k)(1.2m)(330.9k)(673.2k)(839.1k)(1.6m)

Income tax expense

Net Income

(1.3m)(1.6m)(946.9k)(760.3k)(1.1m)(518.9k)(750.3k)(1.1m)677.4k(451.4k)(1.5m)(1.0m)886.6k(121.4k)(363.3k)(352.9k)(1.7m)(2.5m)(424.6k)(931.7k)(139.2k)(1.2m)(330.9k)(673.2k)(839.1k)(1.6m)

U.S. Stem Cell Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

34.2k2.8k69.9k35.2k4.8k239.0k172.8k6.7k219.0k91.2k46.6k71.0k93.5k65.7k275.4k130.8k246.0k619.1k929.7k956.6k1.7m1.7m1.4m749.4k587.5k78.1k

Accounts Receivable

304.01.1k1.7k220.08.9k48.8k105.6k153.9k78.5k98.5k93.8k48.8k41.6k33.9k59.9k33.2k115.0k75.9k47.4k32.5k64.2k12.2k20.2k

Prepaid Expenses

86.6k99.0k88.4k56.1k71.0k79.4k3.1k1.7k4.0k26.2k258.01.8k9.2k28.1k38.1k38.1k38.1k38.1k38.1k

Inventories

64.3k64.1k63.3k63.3k63.3k30.5k33.7k40.4k41.0k38.0k59.0k76.7k66.1k72.6k70.9k43.7k46.4k

Current Assets

185.1k165.9k221.7k154.9k140.2k320.1k176.1k15.6k269.4k200.8k226.6k149.7k193.8k168.6k354.7k206.2k320.3k720.0k1.0m1.1m1.9m1.8m1.6m922.7k681.5k182.8k

PP&E

28.5k20.7k11.2k8.2k4.8k1.1k570.0492.08.2k13.4k13.4k12.3k11.0k9.6k13.0k11.7k22.8k608.5k555.2k503.5k397.6k345.9k294.3k191.0k139.3k87.7k

Total Assets

371.4k344.7k332.0k217.7k199.7k375.8k231.3k70.7k287.6k224.2k248.5k221.7k277.8k262.9k432.8k283.4k413.3k1.4m1.6m1.7m2.4m2.2m2.1m1.3m878.9k656.2k

Accounts Payable

2.4m2.4m2.6m2.6m2.6m2.5m2.4m2.4m2.5m2.2m2.1m2.0m2.1m2.0m1.4m1.3m1.4m1.5m1.4m1.4m1.4m1.3m1.3m1.1m1.1m1.1m

Short-term debt

(3.0m)67.4k69.2k73.2k75.1k77.0k4.5k208.9k214.2k219.5k210.4k1.4m1.5m

Current Liabilities

12.6m12.6m12.5m12.8m13.5m13.3m13.4m13.4m11.4m9.8m10.3m11.1m8.2m7.7m5.9m5.7m7.0m6.6m6.4m6.4m6.7m7.2m6.2m5.7m7.8m8.9m

Long-term debt

496.3k349.4k206.1k189.8k1.3m1.3m1.3m1.2m1.2m1.2m1.2m1.2m1.2m1.3m1.3m1.3m

Non-Current Liabilities

2.2m2.2m2.2m2.3m2.4m2.8m2.1m2.0m2.9m2.6m729.4k835.8k

Total Debt

496.3k(3.0m)349.4k206.1k189.8k1.3m1.4m1.3m1.3m1.3m1.3m1.2m1.2m1.5m1.5m1.5m1.5m1.4m1.5m

Total Liabilities

13.1m12.6m9.4m9.0m8.1m7.9m9.2m8.9m8.8m9.2m8.8m9.2m9.1m8.3m8.6m9.8m

Common Stock

45.5k70.5k132.9k137.0k167.8k190.5k227.5k319.3k420.9k506.6k533.7k670.5k803.7k978.02.8k8.9k29.2k327.6k336.5k339.3k358.7k366.4k368.3k389.7k393.7k397.7k

Preferred Stock

20.0k20.0k20.0k20.0k20.0k20.0k20.0k20.0k20.0k20.0k20.0k

Additional Paid-in Capital

96.1m97.6m99.6m99.7m99.9m100.9m101.9m103.1m104.7m106.9m107.9m109.9m110.7m112.1m115.0m115.1m115.7m118.8m119.6m120.1m121.0m121.6m121.9m123.0m123.2m123.4m

Retained Earnings

(118.0m)(119.4m)(121.5m)(120.6m)(120.7m)(122.4m)(122.8m)(124.5m)(126.6m)(127.0m)(128.0m)(127.8m)(129.0m)(129.3m)(130.5m)(131.3m)(132.9m)

Total Equity

(12.7m)(12.3m)(12.2m)(12.6m)(13.8m)(14.0m)(13.8m)(13.7m)(12.2m)(10.4m)(10.8m)(10.9m)(9.2m)(8.7m)(7.7m)(7.6m)(8.7m)(7.5m)(7.1m)(7.5m)(6.4m)(7.0m)(7.0m)(7.1m)(7.7m)(9.1m)

Debt to Equity Ratio

0 x0.2 x0 x0 x0 x-0.1 x-0.2 x-0.2 x-0.2 x-0.1 x-0.2 x-0.2 x-0.2 x-0.2 x-0.2 x-0.2 x-0.2 x-0.2 x

Debt to Assets Ratio

1.3 x-13.8 x1.2 x0.9 x0.8 x4.8 x5.2 x3.1 x4.5 x3.1 x0.9 x0.7 x0.7 x0.6 x0.7 x0.7 x1.2 x1.6 x

Financial Leverage

0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x-0.1 x0 x0 x-0.2 x-0.2 x-0.2 x-0.4 x-0.3 x-0.3 x-0.2 x-0.1 x-0.1 x

U.S. Stem Cell Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(2.5m)(3.7m)(946.9k)(1.7m)(2.8m)(518.9k)(1.3m)(2.4m)677.4k226.0k(1.2m)(1.0m)(161.6k)(283.0k)(363.3k)(716.2k)(2.4m)(2.5m)(2.9m)(3.8m)(139.2k)(1.4m)(1.7m)(673.2k)(1.5m)(3.2m)

Depreciation and Amortization

19.0k26.7k4.3k8.2k11.6k769.01.3k1.3k863.02.0k3.7k1.3k2.6k3.9k1.2k2.4k3.9k18.8k72.1k125.0k52.2k103.8k155.5k51.7k103.3k155.0k

Accounts Receivable

3.5k3.2k2.4k(362.0)1.1k(7.6k)(38.8k)(114.4k)(162.7k)16.9k(3.1k)1.6k(35.5k)(22.9k)(20.0k)(35.4k)(15.0k)(97.6k)(42.1k)865.0(22.1k)(67.5k)(13.4k)(33.1k)

Inventories

416.044.9k417.063.0k63.0k63.0k(13.1k)(16.3k)(23.0k)1.2k4.2k(16.8k)(6.3k)4.3k(2.3k)22.3k49.5k46.9k

Accounts Payable

369.7k268.0k254.2k222.6k272.6k(12.5k)(71.1k)(76.2k)172.8k255.4k628.7k114.5k243.0k324.0k(62.9k)13.8k78.5k205.5k305.1k519.4k188.2k204.5k332.6k123.9k195.9k269.1k

Cash From Operating Activities

(704.2k)(1.2m)(84.4k)(553.5k)(905.4k)(546.4k)(1.1m)(1.6m)(257.8k)(507.1k)(747.2k)(384.3k)(646.7k)(789.5k)(62.1k)(165.6k)(113.4k)268.3k785.7k1.0m688.7k668.2k577.2k(340.4k)(535.8k)(991.1k)

Purchases of PP&E

(933.0)(933.0)(6.4k)(8.1k)(894.0)(894.0)(894.0)(12.6k)(1.2k)

Cash From Investing Activities

(933.0)(933.0)(6.4k)(8.1k)(5.9k)(61.2k)(168.6k)42.7k57.7k95.1k580.0k640.0k688.8k45.0k109.0k214.2k80.9k166.8k166.8k

Short-term Borrowings

(291.7k)(256.7k)(63.7k)(223.3k)(223.3k)(55.4k)(90.8k)(143.8k)(70.9k)(210.8k)(228.8k)(93.7k)(251.7k)(350.3k)(159.6k)(322.5k)(484.4k)(169.3k)(232.4k)(381.0k)

Cash From Financing Activities

735.0k1.2m117.5k552.8k874.3k785.4k1.3m1.6m430.5k558.4k755.7k424.4k764.8k987.0k236.4k180.4k205.9k(499.9k)(766.7k)(1.0m)(2.4k)(94.4k)(330.1k)(348.2k)(400.6k)(454.7k)

Net Change in Cash

30.9k(511.0)33.1k(1.7k)(32.0k)239.0k172.8k6.7k172.8k45.0k365.034.3k56.9k29.0k217.0k72.5k187.6k348.4k659.0k685.9k731.2k682.8k461.4k(607.7k)(769.6k)(1.3m)

Interest Paid

129.6k173.9k128.7k265.7k403.6k104.0k277.7k514.0k85.0k161.5k161.5k108.5k191.8k273.9k13.4k31.7k49.2k70.1k70.1k151.2k132.0k497.2k808.2k324.8k622.4k633.9k

Income Taxes Paid

U.S. Stem Cell Ratios

USDQ2, 2011

Debt/Assets

1.3 x